The U.S. Department of Health and Human Services outlined efforts designed to speed up early-stage clinical trials by 6 to 12 months, as the biotech community convenes for BIO 2026 in San Diego. The plan aims to help regain time in early development and encourage U.S.-based trial starts. The announcement ties into the broader push for faster Investigational New Drug (IND) activity through changes to existing pathways and potential permanent process reforms. The goal is to reduce friction in trial initiation, thereby narrowing timelines between IND clearance and active enrollment. For developers, the primary question is how the agencies will operationalize the timeline reductions across sponsors, IRBs, and trial execution. Even modest process acceleration can affect capital allocation and the probability of hitting pivotal program milestones. The policy move also signals heightened attention to global competition in early clinical development capacity.